To Get Full Access :

Lynavoy

Lynavoy (linerixibat) is a prescription medication used in adults to treat cholestatic pruritus associated with primary biliary cholangitis (PBC), a chronic liver disease marked by bile acid buildup and persistent itching.

Unlike conventional symptomatic treatments, Lynavoy works by inhibiting the ileal bile acid transporter (IBAT) in the intestine, reducing bile acid reabsorption and promoting their elimination. This helps lower circulating bile acid levels and directly targets the cause of itching.

Cholestatic pruritus can significantly impact sleep, daily functioning, and overall quality of life. With targeted therapies like Lynavoy, patients can experience meaningful relief and improved comfort.

Lynavoy is taken orally and is intended for ongoing management under medical supervision.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Linerixibat
  • Innovator :

    GLAXOSMITHKLINE LLC
  • Approval Date :

    17-Mar-26
  • NCE-1 Date :

    17-Mar-30
  • NCE Date :

    17-Mar-31
  • Dosage Form :

    Oral Tablet
  • Strength :

    40MG
  • Therapeutic Category :

    Ileal Bile Acid Transporter (IBAT) Inhibitor
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA
  • 2026 :

    27
  • 2027 :

    52
  • 2028 :

    105
  • 2029 :

    148
  • 2030 :

    197
  • 2031 :

    239
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?